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LONG TERM OUTCOMES OF ENTECAVIR MONOTHERAPY AFTER LIVER 
TRANSPLANTATION FOR HEPATITIS B - 5 YEARS DATA 
 
Tiffany C.L. Wong, James Y.Y. Fung, M.Y. Chan, Kenneth S.H. Chok, T.T. Cheung, Albert C.Y. 
Chan, W.C. Dai, S.C. Chan, C.M. Lo. Surgery, The University of Hong Kong, Hong Kong, Hong 
Kong; Medicine, The University of Hong Kong, Hong Kong, Hong Kong. 
 
BACKGROUND: Previous study has shown that entecavir monotherapy is effective and safe to 
prevent hepatitis B (HBV) recurrence after liver transplantation (LT) but long-term data is 
lacking. The aim of the current study is to review the long-term results of entecavir monotherapy 
in HBV patients after LT. 
 
METHODS: Patients who underwent LT for HBV related disease and received entecavir 
monoprophylaxis in our centre from November 2007 to July 2009 were included. Primary 
outcome was HBV recurrence: 1) virological rebound as defined as ≥1logIU/ml increase of HBV 
DNA and 2) HBsAg seropositivity. Secondary endpoint was assessment of degree of fibrosis/ 
cirrhosis in liver graft using transient elastography (Fibroscan). Data on patients' demographic, 
liver function and HBV serology were retrieved from a prospectively collected database. 
Fibroscan was done by two operators and examinations were reliable if ≥10 valid measurements 
were acquired with success rate (number of valid acquisitions/ number of attempts) >60%. 
Significant fibrosis and cirrhosis were defined as >8.1kPa and >11kPa respectively. 
 
RESULTS: 65 patients with a median follow-up of 65 months were included. 9 (13.8%) of the 
patients died during study period. There was no mortality or graft failure due to HBV recurrence. 
At the end of 5th year, HBsAg seroclearance and complete HBV DNA suppression to 
undetectable level were 88% and 100% respectively. Two patients defaulted fibroscan. Overall 
success rate for fibroscan was 50/54 patients (92.6%). There were 4 failures due to thick chest 
wall and narrow intercostal space. The median liver stiffness of 5.9kPa (2.5-14.8kPa) and it 
was >11 kPa in 3 patients. 
 
CONCLUSION: Entecavir monoprophylaxis is effective and safe as against HBV recurrence 
after LT and HBsAg seroclearance of 88% and complete HBV DNA suppression were achieved 
at 5 years. The clinical importance of HBsAg positivity in the absence of virological rebound 
remains uncertain. 
